GPR120/FFAR4 protects retinal vascular endothelial cells against high glucose injury via suppressing ROS-ERS mediated apoptosis

GPR120/FFAR4通过抑制ROS-ERS介导的细胞凋亡来保护视网膜血管内皮细胞免受高糖损伤。

阅读:1

Abstract

AIM: To evaluate the role of reactive oxygen species-endoplasmic reticulum stress (ROS-ERS) in the cellular protection of G protein-coupled receptor 120 (GPR120/FFAR4) against high glucose (HG) induced human retinal vascular endothelial cell (HRVEC) injury and its underlying mechanisms. METHODS: HRVECs were divided into the control group, GW9508 (an agonist of GPR120) group, HG group, and HG+GW9508 group. The cell proliferation and apoptosis were assessed by cell counting kit-8 and annexin V-FITC/PI apoptosis detection kit, respectively. Western blotting analysis was performed to assess the protein expressions of Bax, Bcl-2, activating transcription factor 6 (ATF6), PKR-like endoplasmic reticulum kinase (PERK), and inositol-requiring enzyme 1 (IRE1). The ROS assay kit was used for the detection of ROS production. Then the cells were transfected with siRNA of GPR120 and the ROS level and protein levels of ATF6, PERK, and IER1 were compared. RESULTS: GW9508 promoted the proliferation of HRVECs, which was significantly reduced by the stimulation of HG. GW9508 remarkably reduced the apoptosis rate of HRVECs under HG and the expression of proapoptotic protein Bax, while increased the expression of antiapoptotic protein Bcl-2. Under HG condition, a significant increase of ROS production was noticed in HRVECs, and GW9508 treatment greatly decreased it. The over-expressions of ERS-related proteins ATF6, PERK, and IER1 under HG were down-regulated by GW9508 treatment. After successfully transfected with siGPR120, the effects of GW9508 on the production of ROS as well as the expressions of ATF6, PERK, and IER1 were reversed. CONCLUSION: GPR120 protects HRVECs against HG induced apoptosis, and suppressing ROS-ERS pathway is one of the mechanisms involved. Activation of GPR120 may be considered as a potential therapeutic target for diabetic retinopathy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。